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How Much CABG Is Good For Us? 
  In 1977 the Society of Thoracic and Cardiovascular Surgeons of Great 
Britain and Northern Ireland established its Cardiac Surgical Registry with the 
hope that it would “promote the rational use and future planning” of cardiac 
surgery.  The Registry revealed important developments.  The use of coronary 
artery bypass grafting (CABG) doubled by 1982.  Marked geographic variation in 
CABG utilization also emerged, with rates in London 10-times higher that those 
in Oxford or the South Western regions.  The disparities could be explained, in 
part, as a historical artifact: cardiac surgery centers were first established in 
medical schools, and these were concentrated in London.  Cardiac surgeons 
were more concerned about the overall rate.  Even though the UK CABG rate 
had risen sharply, it compared “unfavourably” with the rate in Australia (which 
was 4-times higher) and the United States (7-times higher).  Why “unfavourably”?  
Which country, if any, had the right rate?  This question has vexed physicians for 
decades.  As coronary heart disease (CHD) tightens its grip as the world’s 
leading cause of death, the answer is of growing importance to global health 
policy. 
  Even though scholars have mapped epidemics for centuries, they only 
recently began making maps surgery and other therapies.  J. Alison Glover might 
have made the first.  On a Friday evening in May 1938 he presented a curious 
talk to the Royal Society of Medicine.  He was concerned not just by the dramatic 
rise of tonsillectomy in England, but also by the marked variations between London neighborhoods.  A child in Enfield was 20-times more likely to have had 
the procedure than one in Hornsey.  Such “strange facts” defied easy 
explanation. 
  Widespread concern, however, did not take root for thirty years.  In 1968 
researchers compared surgery rates in Liverpool, Uppsala, and New England 
and found peculiar patterns of variation.  While Americans led the pack with 
tonsillectomy, prostate surgery, and hernia repair, Swedes removed the most 
appendices and gallbladders.  John Wennberg, meanwhile, studied practice 
variation in Vermont and found 3- to 10-fold variation in surgery rates.  
Neighboring regions often had disparate rates.  These reports and many others 
in the early 1970s revealed variation in surgery rates that did not simply reflect 
variations in the underlying burden of disease. 
  It was at this moment that CABG began its rise to prominence.  Although 
surgeons in New York, Baltimore, Houston, Ann Arbor, and Leningrad had 
dabbled with the procedure in the 1960s, Cleveland Clinic surgeons earned the 
procedure wide acclaim in 1968.  Leading medical centers followed suit.  A map 
of CABG in the early 1970s would have shown a patchy distribution, with a few 
hospitals doing hundreds of cases each year, while most did few or none at all.  
CABG, however, soon colonized the medical marketplace.  By 1975 nearly 400 
hospitals in the United States offered bypass surgery.  The procedure had also 
spread to England, Europe, Argentina, Australia, and beyond. 
  The rise of CABG triggered fierce controversy.  As surgeons ramped up 
their case loads, skeptics argued that the procedure performed no better than medical therapy in most patients.  These tensions sharpened the interest in 
practice variation.  The UK Registry exposed marked disparities within England.  
Similar variation was found within Australia and the United States.  As the 
problem of “unwarranted variation” captured more and more attention, 
researchers collected data in ever increasing detail and analyzed them with ever 
more powerful computers.  Wennberg linked up with a small group of economists 
and health researchers to produce the Dartmouth Atlas of Health Care.  The 
Atlas mined US Medicare data to reveal variations in per capita spending, 
physician density, and procedure rates.  A 1999 report commissioned by the 
American College of Cardiology and the Society of Thoracic Surgeons found the 
now-familiar variations in cardiac care.  The prevalence of cardiac surgeons 
varied 5-fold and cardiologists 6-fold.  Procedures varied as well, with 5-fold and 
8-fold differences for CABG and angioplasty. 
  Recognition of pervasive practice variation caused a stir.  In 1983 the US 
Institute of Medicine convened a conference on geographic disparities.  The 
Institute’s president, Frederick Robbins, worried about “’the potentially damning 
evidence that these great variations represent’”: “’it looks bad, and it looks bad 
because it is bad.  It is not an appropriate way for a profession to behave.’”  
Clinicians remained convinced that the variations in CABG and other therapies 
did not simply reflect variations in the underlying burden of disease.  Instead, 
variation reflected a sordid mix of other factors.  When the 1968 international 
comparisons found lower rates of surgery in Liverpool than in Uppsala or New 
England, the researchers wondered whether the “absence of financial incentives to the surgeons to operate may be a factor in restraining the scalpel.”  Did the 
presence of twelve ear nose and throat surgeons in Liverpool, compared with just 
one urologist, account for that city’s high rate of tonsillectomy and low rate of 
prostatectomy?  The team noted wryly “that whereas the tonsils have their 
predator, the prostate is left to flourish unattended.” 
  Subsequent studies looked beyond financial conflicts of interest and 
supplier-induced demand to consider everything from the influence of local 
training programs to variations in national character.  Even the RAND 
Corporation, the Cold War think tank famous for formulating the strategy of 
mutually assured destruction, entered the fray.  In 1985 it assembled two panels 
of English doctors and one panel of American doctors and presented each with 
clinical vignettes of CABG patients.  English doctors rated 35% of the cases 
“inappropriate,” while the Americans flagged only 13%.  Since the panels were 
asked to ignore cost, the researchers concluded that “differences between them 
probably relate to their interpretation of scientific publications and to cultural 
factors that are difficult to identify.”  In some cases the judgment has been 
starker.  One Louisiana cardiologist was indicted in 2006 on charges that he 
falsified clinical findings to justify unnecessary angioplasty and stenting.  
Convicted in 2009, he was sentenced to ten years in prison. 
  As debate continues about the causes of unwarranted variation, 
physicians and health systems researchers continue to refine their data.  The 
UK’s Registry morphed into the National Adult Cardiac Surgical Database, which 
released its 6th annual report in 2008.  A 2005 report from the Chief Medical Officer of the Department of Health examined NHS data and found that allocation 
of revascularization was “not currently equitable.”  A King’s Fund investigation 
confirmed this in 2011: CABG rates ranged from 34/100,000 in the Westminster 
PCT to 197/100,000 in Berkshire PCT.  Was one of these rates right?  The 
targets set by the Department of Health and the NHS keep shifting, from 
30/100,000 in 1984 to 150/100,000 in 2000. 
  International comparisons are equally troubling.  In 1984 British surgeons 
thought that their CABG rate was unfavourably low, but many people now 
consider the US revascularization rates to be too high: patients in the United 
States do no better after heart attacks than their less frequently revascularized 
Canadian peers.  OECD data from 2009 show a 7-fold variation in angioplasty 
rates between Germany and Ireland, with the United States and England 
distributed in between.  These disparities are dwarfed by those beyond Europe.  
Barely visible at the bottom of the OECD chart sat Mexico, with an angioplasty 
rate scarcely 1/300th of that in Germany despite a similar CHD mortality rate.  
Revascularization is even less accessible in China and India. 
  It might once have been acceptable to dismiss these disparities as 
appropriate.  CHD, after all, was long seen as a disease of the industrialized 
west.  But health officials have known for the past two decades that this is not the 
case.  In its 1993 World Development Report, the World Bank reported that CHD 
had already become the leading cause of death worldwide.  India now has more 
heart attack deaths than any other country.  Turkmenistan and Ukraine have the 
highest CHD mortality rates.  Investments in cardiac care have not followed the rising tide of deaths.  It may be true that coronary revascularization is over-used 
in Germany and the United States, but even the “low” rate in England towers 
above that in Mexico.  The World Bank and the Institute of Medicine have 
encouraged aspirin, beta blockers, and other low cost medications while advising 
poor countries to avoid “sophisticated, expensive technologies” such as 
angiography, angioplasty, and CABG.  Recent advocacy has finally pushed non-
communicable disease onto the global health agenda.  Initial efforts culminated 
last fall when world leaders met in New York City for the General Assembly on 
the Prevention and Control of Non-communicable Diseases.  But even there the 
attention remained focused on tobacco, diet, and lifestyle: “Prevention must be 
the cornerstone of the global response to noncommunicable diseases.” 
  Should our response to the global spread of CHD be limited to 
prevention?  The conventional wisdom holds that low- and middle-income 
countries should not invest in CABG and angioplasty: the techniques are said to 
be too difficult and too expensive to deploy in resource-poor settings.  But that 
exact same critique was once leveled against antiretroviral therapy for AIDS -- it 
was too difficult to ensure adherence with the complex regimens, and the drugs 
were too expensive.  It took many years of concerted effort by AIDS activists to 
shift the consensus from prevention to treatment, an effort that culminated in the 
Global Fund for the Prevention of AIDS, Tuberculosis and Malaria and the 
President’s Emergency Program for AIDS Relief. 
  No one has yet identified the lack of access to coronary revascularization 
as a human rights crisis.  There is no Global Fund or President’s Emergency Program for Heart Attacks.  Should there be?  The inability of physicians in 
England, Europe, and the United States to establish and achieve target rates for 
CABG and angioplasty foretells a stormy course before progress is made 
towards global health equity in cardiac care.  The revascularization rate in the 
United States is likely too high and the rate in Mexico is surely too low.  What 
rate is the right rate?  England might actually represent a happy mean, but 
physicians have not yet learned how to provide a convincing answer.  Nor have 
they developed a plan to help the millions of heart attack patients each year in 
low- and middle-income countries whose lives could be saved with prompt use of 
these interventions. 
 
David S. Jones 
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